科伦博泰生物-B宣布,其创新药物SKB103的新药临床试验申请已正式获得中国国家药品监督管理局批准,将针对晚期实体瘤开展临床研究。此次获批标志着该药物在肿瘤治疗领域迈出关键一步,为后续研发奠定了重要基础。
科伦博泰生物-B宣布,其创新药物SKB103的新药临床试验申请已正式获得中国国家药品监督管理局批准,将针对晚期实体瘤开展临床研究。此次获批标志着该药物在肿瘤治疗领域迈出关键一步,为后续研发奠定了重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.